Radiolabeling, Quality Control and In Vivo Imaging of Multimodal Targeted Nanomedicines - Archive ouverte HAL Access content directly
Journal Articles Pharmaceutics Year : 2022

Radiolabeling, Quality Control and In Vivo Imaging of Multimodal Targeted Nanomedicines

(1, 2) , (1) , (3) , (4) , (1) , (5, 6) , (5, 6) , (1)
1
2
3
4
5
6

Abstract

Following our previous study on the development of EGFR-targeted nanomedicine (NM-scFv) for the active delivery of siRNA in EGFR-positive cancers, this study focuses on the development and the quality control of a radiolabeling method to track it in in vivo conditions with nuclear imaging. Our NM-scFv is based on the electrostatic complexation of targeted nanovector (NV-scFv), siRNA and two cationic polymers. NV-scFv comprises an inorganic core, a fluorescent dye, a polymer layer and anti-EGFR ligands. To track NM-scFv in vivo with nuclear imaging, the DTPA chemistry was used to radiolabel NM-scFv with 111In. DTPA was thiolated and introduced onto NV-scFv via the maleimide chemistry. To obtain suitable radiolabeling efficiency, different DTPA/NV-scFv ratios were tested, including 0.03, 0.3 and 0.6. At the optimized ratio (where the DTPA/NV-scFv ratio was 0.3), a high radiolabeling yield was achieved (98%) and neither DTPA-derivatization nor indium-radiolabeling showed any impact on NM-scFv’s physicochemical characteristics (DH ~100 nm, PDi < 0.24). The selected NM-scFv-DTPA demonstrated good siRNA protection capacity and comparable in vitro transfection efficiency into EGFR-overexpressing cells in comparison to that of non-derivatized NM-scFv (around 67%). Eventually, it was able to track both qualitatively and quantitatively NM-scFv in in vivo environments with nuclear imaging. Both the radiolabeling and the NM-scFv showed a high in vivo stability level. Altogether, a radiolabeling method using DTPA chemistry was developed with success in this study to track our NM-scFv in in vivo conditions without any impact on its active targeting and physicochemical properties, highlighting the potential of our NM-scFv for future theranostic applications in EGFR-overexpressing cancers.
Fichier principal
Vignette du fichier
2022_Nguyen_pharmaceutics_vol14_art-02679.pdf (2.71 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-03925149 , version 1 (05-01-2023)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Phuoc-Vinh Nguyen, Emilie Allard-Vannier, Nicolas Aubrey, Christine Labrugère-Sarroste, Igor Chourpa, et al.. Radiolabeling, Quality Control and In Vivo Imaging of Multimodal Targeted Nanomedicines. Pharmaceutics, 2022, 14 (12), pp.2679. ⟨10.3390/pharmaceutics14122679⟩. ⟨hal-03925149⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More